+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Recombinant Coagulation Factor Concentrate Market - Global Forecast 2026-2032- Product Image
Recombinant Coagulation Factor Concentrate Market - Global Forecast 2026-2032- Product Image
Sale

Recombinant Coagulation Factor Concentrate Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6143163
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Recombinant Coagulation Factor Concentrate Market is projected to reach USD 5.12 Billion in 2026. It is expected to continue growing at a CAGR of 10.53%, reaching USD 9.45 Billion by 2032.

Recombinant Coagulation Factor Concentrates: Executive Overview

Recombinant coagulation factor concentrates are biologic therapies used to replace deficient or dysfunctional clotting factors, particularly in inherited bleeding disorders such as hemophilia A and B. Their clinical value is tied to prevention and treatment of bleeding, support for surgery and trauma care, and reduction of exposure to plasma-derived pathogens. Access, diagnosis, treatment adherence, inhibitor management, and specialized infusion services remain central determinants of patient outcomes.

Treatment Is Shifting Toward Proactive, Personalized Care

The treatment landscape is moving from episodic control of bleeding toward individualized prophylaxis, home-based administration, extended-interval regimens, and integrated monitoring. Clinical decisions increasingly consider bleeding phenotype, pharmacokinetics, age, lifestyle, venous access, inhibitor status, and patient preference. Health systems are also emphasizing early diagnosis, comprehensive hemophilia centers, structured registries, and coordinated multidisciplinary care.

Artificial Intelligence Strengthens Diagnosis, Dosing, and Care Coordination

Artificial intelligence can support earlier recognition of bleeding disorders by identifying patterns in clinical records, laboratory results, and family histories. In treatment management, predictive tools may help estimate factor utilization, personalize dosing intervals, flag adherence risks, and identify patients who need inhibitor testing or specialist review. Its practical value depends on representative clinical data, transparent validation, privacy safeguards, interoperability, and continued clinician oversight; AI should augment rather than replace hematology expertise.

Regional Differences Reflect Diagnosis, Infrastructure, and Reimbursement

North America generally benefits from specialized treatment networks, advanced laboratory capacity, and established home-infusion pathways, although affordability and insurance design can affect continuity. Europe combines mature clinical guidance with varied national procurement and reimbursement systems. Asia-Pacific presents strong opportunities to expand diagnosis, local treatment capacity, and access beyond major urban centers. Latin America continues to face uneven specialist coverage, supply reliability, and public-sector access. In the Middle East, investment in tertiary care and national programs coexists with differences in registry quality and referral pathways. Africa remains constrained by limited diagnosis, laboratory infrastructure, specialist availability, and treatment access, making capacity building and sustainable procurement particularly important.

Economic and Policy Groups Have Distinct Access Priorities

Across ASEAN, improving diagnosis, regional referral networks, cold-chain reliability, and affordability is central to broader access. BRICS members span substantial differences in domestic manufacturing, public procurement, specialist capacity, and rural coverage, creating opportunities for coordinated standards and technology transfer. The European Union benefits from cross-border scientific collaboration while national reimbursement and procurement decisions remain important. G7 systems generally have strong clinical infrastructure but continue to address treatment cost, health inequities, and long-term care coordination. GCC countries are expanding specialized services and national health capabilities, while NATO members require resilient medical supply chains and continuity planning across diverse health systems.

Country Priorities Range from Advanced Care to Basic Diagnostic Expansion

Australia emphasizes specialist coordination, national blood-disorder services, and equitable access across geographically dispersed communities. Brazil and Mexico continue to prioritize public-sector reach, diagnosis, and reliable distribution. Canada and the United States have extensive specialist capacity, while coverage design, affordability, and geographic equity remain relevant concerns. China and India are expanding diagnostic and treatment infrastructure across large and diverse populations. France, Germany, Italy, Spain, and the United Kingdom combine established hematology services with ongoing attention to procurement, outcomes monitoring, and sustainable reimbursement. Japan and South Korea have advanced clinical systems that support personalized care and safety monitoring. Russia’s priorities include continuity of supply, specialist access, and development of domestic health-system capacity.

Industry Leaders Should Prioritize Reliable, Patient-Centered Access

Leaders should strengthen supply resilience through diversified manufacturing, validated distribution, and contingency planning for critical biologics. They should support evidence-based individualized dosing, patient education, adherence services, home administration where appropriate, and rapid access to inhibitor testing. Partnerships with treatment centers, payers, patient organizations, and public-health agencies can improve diagnosis and registry quality. Digital and AI-enabled tools should be introduced with clinical validation, cybersecurity controls, explainability, and measurable outcomes. Regional strategies should be adapted to local infrastructure rather than relying on a single global access model.

Methodology Uses Structured Review of Clinical, Policy, and Access Evidence

This executive summary is based on a structured qualitative review of the recombinant coagulation factor concentrate landscape, organized around therapeutic use, care delivery, technology adoption, regional conditions, policy groups, and country-level health-system characteristics. Evidence interpretation should prioritize peer-reviewed clinical literature, treatment guidelines, regulatory publications, public procurement information, patient registries, and official health statistics. Findings are framed as directional insights and do not include market estimates, shares, sizing, or forecasts. Geographic comparisons account for differences in diagnosis, reimbursement, laboratory capacity, specialist networks, and supply infrastructure.

Sustainable Progress Depends on Integration Across the Care Pathway

Recombinant coagulation factor concentrates remain an important component of modern bleeding-disorder care, but clinical benefit depends on more than product availability. Earlier diagnosis, individualized treatment, inhibitor management, reliable supply, specialist coordination, and equitable reimbursement must advance together. Responsible use of digital tools and AI can improve decision support and continuity when embedded in validated, patient-centered systems. Progress will be strongest where manufacturers, clinicians, governments, payers, and patient communities align around measurable outcomes and durable access.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Recombinant Coagulation Factor Concentrate Market, by Product Type
7.1. Introduction
7.2. Recombinant Factor IX
7.3. Recombinant Factor VIII
8. Recombinant Coagulation Factor Concentrate Market, by Disease Indication
8.1. Introduction
8.2. Acquired Coagulation Factor Deficiencies
8.3. Congenital Factor VII Deficiency
8.4. Congenital Factor XIII Deficiency
8.5. Congenital Fibrinogen Deficiency
8.6. Hemophilia A
8.7. Hemophilia B
9. Recombinant Coagulation Factor Concentrate Market, by Therapy Type
9.1. Introduction
9.2. On-Demand Therapy
9.3. Prophylaxis Therapy
10. Recombinant Coagulation Factor Concentrate Market, by End User
10.1. Introduction
10.2. Hemophilia Treatment Centers
10.3. Home Care Settings
10.4. Hospitals
10.5. Research & Academic Institutions
10.6. Specialty Clinics
11. Recombinant Coagulation Factor Concentrate Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Recombinant Coagulation Factor Concentrate Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Recombinant Coagulation Factor Concentrate Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Bayer AG
15.2. Bio Products Laboratory Ltd
15.3. Biogen Inc
15.4. Boehringer Ingelheim
15.5. CSL Behring
15.6. Grifols S.A.
15.7. Kedrion S.p.A.
15.8. LFB S.A.
15.9. Novo Nordisk A/S
15.10. Octapharma AG
15.11. Pfizer Inc
15.12. Sanofi S.A.
15.13. Shanghai RAAS Blood Products Co., Ltd
15.14. Swedish Orphan Biovitrum AB (Sobi)
15.15. Takeda Pharmaceutical Company Limited
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Recombinant Coagulation Factor Concentrate Market, Years Considered for the Study
FIGURE 2. Global Recombinant Coagulation Factor Concentrate Market, Research Design
FIGURE 3. Global Recombinant Coagulation Factor Concentrate Market, Research Framework
FIGURE 4. Global Recombinant Coagulation Factor Concentrate Market, Data Triangulation
FIGURE 5. Global Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2025 vs 2032 (%)
FIGURE 9. Global Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 11. Global Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Recombinant Coagulation Factor Concentrate Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Recombinant Coagulation Factor Concentrate Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Recombinant Coagulation Factor Concentrate Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Recombinant Coagulation Factor Concentrate Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Recombinant Coagulation Factor Concentrate Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Recombinant Coagulation Factor Concentrate Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Recombinant Coagulation Factor Concentrate Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Recombinant Coagulation Factor Concentrate Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Recombinant Coagulation Factor Concentrate Market Segmentation & Coverage
TABLE 2. Global Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 3. Global Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Recombinant Factor IX Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Recombinant Factor IX Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Recombinant Factor IX Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Recombinant Factor VIII Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Recombinant Factor VIII Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Recombinant Factor VIII Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 11. Global Acquired Coagulation Factor Deficiencies Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Acquired Coagulation Factor Deficiencies Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Acquired Coagulation Factor Deficiencies Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Congenital Factor VII Deficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Congenital Factor VII Deficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Congenital Factor VII Deficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Congenital Factor XIII Deficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Congenital Factor XIII Deficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Congenital Factor XIII Deficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Congenital Fibrinogen Deficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Congenital Fibrinogen Deficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Congenital Fibrinogen Deficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Hemophilia A Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Hemophilia A Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Hemophilia A Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Hemophilia B Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Hemophilia B Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Hemophilia B Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 30. Global On-Demand Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global On-Demand Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global On-Demand Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Prophylaxis Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Prophylaxis Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Prophylaxis Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 37. Global Hemophilia Treatment Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Hemophilia Treatment Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Hemophilia Treatment Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Research & Academic Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Research & Academic Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Research & Academic Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Recombinant Coagulation Factor Concentrate Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Recombinant Coagulation Factor Concentrate Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 58. North America Recombinant Coagulation Factor Concentrate Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. North America Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 60. North America Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 61. North America Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 62. North America Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 63. Latin America Recombinant Coagulation Factor Concentrate Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Latin America Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 65. Latin America Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 66. Latin America Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 67. Latin America Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 68. Europe Recombinant Coagulation Factor Concentrate Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Europe Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 70. Europe Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 71. Europe Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 72. Europe Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 73. Middle East Recombinant Coagulation Factor Concentrate Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Middle East Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 75. Middle East Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 76. Middle East Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 77. Middle East Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. Africa Recombinant Coagulation Factor Concentrate Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Africa Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 80. Africa Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 81. Africa Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 82. Africa Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. Global Recombinant Coagulation Factor Concentrate Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. ASEAN Recombinant Coagulation Factor Concentrate Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. ASEAN Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 86. ASEAN Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 87. ASEAN Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 88. ASEAN Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. GCC Recombinant Coagulation Factor Concentrate Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. GCC Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 91. GCC Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 92. GCC Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 93. GCC Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. European Union Recombinant Coagulation Factor Concentrate Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. European Union Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 96. European Union Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 97. European Union Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 98. European Union Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. BRICS Recombinant Coagulation Factor Concentrate Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. BRICS Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 101. BRICS Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 102. BRICS Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 103. BRICS Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 104. G7 Recombinant Coagulation Factor Concentrate Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. G7 Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 106. G7 Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 107. G7 Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 108. G7 Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 109. NATO Recombinant Coagulation Factor Concentrate Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. NATO Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 111. NATO Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 112. NATO Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 113. NATO Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. Global Recombinant Coagulation Factor Concentrate Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. United States Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 116. United States Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 117. United States Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 118. United States Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 119. United States Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. Canada Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 121. Canada Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 122. Canada Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 123. Canada Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 124. Canada Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. Mexico Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 126. Mexico Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 127. Mexico Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 128. Mexico Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 129. Mexico Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. Brazil Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 131. Brazil Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 132. Brazil Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 133. Brazil Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 134. Brazil Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. United Kingdom Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 136. United Kingdom Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 137. United Kingdom Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 138. United Kingdom Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 139. United Kingdom Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. Germany Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 141. Germany Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 142. Germany Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 143. Germany Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 144. Germany Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. France Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 146. France Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 147. France Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 148. France Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 149. France Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. Russia Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 151. Russia Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 152. Russia Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 153. Russia Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 154. Russia Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. Italy Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 156. Italy Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 157. Italy Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 158. Italy Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 159. Italy Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Spain Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 161. Spain Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 162. Spain Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 163. Spain Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 164. Spain Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. China Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 166. China Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 167. China Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 168. China Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 169. China Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. India Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 171. India Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 172. India Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 173. India Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 174. India Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Japan Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 176. Japan Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 177. Japan Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 178. Japan Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 179. Japan Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. Australia Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 181. Australia Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 182. Australia Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 183. Australia Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 184. Australia Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. South Korea Recombinant Coagulation Factor Concentrate Market Size, 2017-2032 (USD Million)
TABLE 186. South Korea Recombinant Coagulation Factor Concentrate Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 187. South Korea Recombinant Coagulation Factor Concentrate Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 188. South Korea Recombinant Coagulation Factor Concentrate Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 189. South Korea Recombinant Coagulation Factor Concentrate Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Global Recombinant Coagulation Factor Concentrate Market Share, by Key Player, 2025
TABLE 191. Global Recombinant Coagulation Factor Concentrate Market, Key Experts

Companies Mentioned

  • Bayer AG
  • Bio Products Laboratory Ltd
  • Biogen Inc
  • Boehringer Ingelheim
  • CSL Behring
  • Grifols S.A.
  • Kedrion S.p.A.
  • LFB S.A.
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc
  • Sanofi S.A.
  • Shanghai RAAS Blood Products Co., Ltd
  • Swedish Orphan Biovitrum AB (Sobi)
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Coagulation Factor Concentrates Market - Global Forecast 2026-2032 - Product Image

Coagulation Factor Concentrates Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Recombinant Coagulation Factors - Global Strategic Business Report - Product Image

Recombinant Coagulation Factors - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Coagulation Factor Concentrates - Global Strategic Business Report - Product Image

Coagulation Factor Concentrates - Global Strategic Business Report

  • Report
  • 254 Pages
  • Global
From
Coagulation Factor Deficiency Market Report 2026 - Product Image

Coagulation Factor Deficiency Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Coagulation Factor Deficiency Epidemiology Forecast 2026-2035 - Product Image

Coagulation Factor Deficiency Epidemiology Forecast 2026-2035

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.